(rivaroxaban)
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
XARELTO® (rivaroxaban)
Medical Information
XARELTO - Reversal Agents in Human Studies - aPCC - Perzborn et al (2014)
Last updated : 05/16/2024
In the Perzborn et al (2014) study, nanofiltered aPCC (FEIBA NF®, 0.2-1.0 U/mL) had the following effects1:
- PT prolongation was significantly reversed by 22%-77% at all aPCC concentrations in plasma spiked with XARELTO 200-1000 ng/mL, and a ceiling effect of reversal occurred at 0.7 U/mL aPCC.
- Clotting time prolongation was partially reversed, and only significantly with XARELTO 1656 ng/mL.
- XARELTO-induced lag time prolongation was reversed by 33%-47%.
- aPCC 0.4 U/mL significantly reversed ETP inhibition (89%) induced by XARELTO 500 ng/mL.
- Cmax inhibition was reversed by 6%-56% at all aPCC concentrations.
aPCC, activated prothrombin complex concentrate; Cmax, maximum plasma concentration; ETP, endogenous thrombin potential; PT, prothrombin time.
Reference
Show Hide
1. Perzborn E, Heitmeier S, Laux V, et al. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res. 2014;133(4):671-681.
